ArticleCancer management and research2025
The Prophylactic Role of Hyperthermic Intraperitoneal Chemotherapy on Spontaneously Ruptured Hepatocellular Carcinoma with Radical Resection: A Retrospective Study.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spontaneous rupture of hepatocellular carcinoma (srHCC) carries a high risk of peritoneal metastasis and poor prognosis. While hyperthermic intraperitoneal chemotherapy (HIPEC) is established for peritoneal metastases in other cancers, its prophylactic role after radical resection of srHCC remains undefined. This study evaluated the efficacy and safety of HIPEC in improving outcomes for srHCC patients post-hepatectomy. Methods: In this retrospective study, 77 patients with srHCC undergoing hepatectomy (2016-2022) were categorized into the HR-HIPEC group (n=30) and the non-HIPEC group (n=47). Clinical features and survival data were analyzed. Results: The HR-HIPEC group demonstrated significantly superior median overall survival (OS: 44 vs 35 months; Conclusion: Prophylactic HIPEC is a safe and feasible adjunct to hepatectomy that significantly improves survival outcomes in srHCC patients without increasing perioperative risks. The choice between the two chemotherapy regimens studied did not affect efficacy, warranting further investigation to optimize protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.